Albany, NY -- (SBWire) -- 02/08/2017 --Osteoporosis is a chronic and life-threatening disease, in which microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone fragility and threat of bone cracks and fractures. Thus, osteoporosis is considered life threatening due to severe injury and associated pain.

Obtain the Sample Containing the Upcoming Market Trends of Osteoporosis Drugs at: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=133

The global osteoporosis market is segmented on the basis of drug class and geography. On the basis of drug class, the global osteoporosis market is segmented into bisphosphonates, parathyroid hormone therapy (PTH) drugs, selective estrogen receptor modulators (SERMs), RANK ligand inhibitors, calcitonin, and other such as others Vitamin D and calcium. This segment also includes drugs that are in the pipeline. Geographically, this market is segmented into Europe, North America, Asia Pacific, and Rest of the World.

Out of the drug class segments, bisphosphonates were the fastest growing segment and held 48.2% of the overall osteoporosis drugs market in 2013. However, analysts predict that pipeline drugs will showcase accelerated growth at a CAGR of 125.20% from 2014 to 2020.The International Osteoporosis Foundation (IOF) stated that at least 9 mn fractures and bone cracks occur every year. In addition to this, about 200 mn women across the world are expected to be victims of osteoporosis with each passing year. With these alarming figures, growth of the global osteoporosis drug is only expected to accelerate. In addition, introduction of new drug classes that hold the promise of overcoming the threat of chronic and generics side effects of the established drugs is yet another factor making a positive influence on the growth of the global osteoporosis drugs market.

In terms of geography, North America holds a major share in the global osteoporosis drugs market. This can be credited to the presence of a huge pool of patients suffering from osteoporosis, growing awareness about the disease, technological advancements and adoption of the same, and presence of state-of-the-art medical infrastructure. However, the research report predicts that Asia Pacific will be the next region to create a huge wave of demand in the osteoporosis drugs market from 2014 to 2020.

Read the Current Market Status of Osteoporosis Drugs at: http://www.transparencymarketresearch.com/osteoporosis-drug-market.html

Some of the important players in the global osteoporosis drugs market are Novartis International AG, Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc., and Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Actavis plc, and Novo Nordisk A/S. The report opens a discussion about the competitive landscape of the global osteoporosis drugs market and states details pertaining to company overview, financial overview, research and development activities, business and marketing strategies, and lists the existing products and those in the pipeline.

About TMR
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.